Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 American College of Rheumatology Core Components and Acute Phase Reactants

From: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

ACR Core Reactant Components and Acute Phase Baseline Week 4 Week 8 Week 12
ACR Core Set Tender joint count (0-68 scale) 14.9 ± 7.1 9.4 ± 7.1* 7.8 ± 7.1* 6.8 ± 6.8*
  Swollen joint count (0-66 scale) 13.2 ± 5.2 8.7 ± 5.6* 7.4 ± 5.5* 6.4 ± 5.2*
  Patient's assessment of pain, mm (0-100 mm VAS)a 66.2 ± 22.3 45.0 ± 26.4* 40.3 ± 26.9* 37.3 ± 27.5*
  Patient's global assessment of disease activity, mm (0-100 mm VAS)b 65.1 ± 22.7 45.1 ± 25.7* 41.0 ± 26.7* 37.4 ± 27.2*
  Physician's global assessment of disease activity, mm (0-100 mm VAS)b 63.6 ± 17.6 40.7 ± 22.5* 33.5 ± 22.4* 29.0 ± 22.7*
  HAQ-DI score (0-3 scale)c 1.5 ± 0.6 1.2 ± 0.7* 1.1 ± 0.7* 1.0 ± 0.7*
Acute Phase Reactant ESR (mm/h) normal value < 20 mm/h 30.3 ± 23.8 20.6 ± 20.1* 20.7 ± 19.7* 20.0 ± 18.6*
  1. *P < 0.001 vs. baseline.
  2. a0 = no pain and 100 = severe pain.
  3. b0 = no disease activity and 100 = extreme disease activity.
  4. c0 = no difficulty and 3 = unable to perform activity.
  5. ACR: American College of Rheumatology; ESR: erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; VAS: visual analog scale.